Tag: NASDAQ: AUTL

Business

Autolus Therapeutics plc (NASDAQ: AUTL) Jumps 12% on New Data In AUTO1 in r/r Indolenty B Cell Lymphoma study

Autolus Therapeutics plc (NASDAQ: AUTL) jumped 12.85% after releasing new AUTO1 (obecabtagene autoleucel, obe-cel) data in refractory/relapsed Adult Acute Lymphoblastic Leukemia (ALL) and r/r indolent B cell lymphomas trials. Autolus presents new data in obe-cel.  The company presented the data at the 2021 European Hematology Association Virtual Congress. As of […]